Biographical Sketch
NamePosition title
Collantes-Estevez, Eduardo Professor of Medicine (Rheumatology)
Education/Training (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
Institution and locationDegreeYear(s)Field of study
University of Córdoba PhD 1984 Medicine/Rheumatology
A. Positions and Honors.
  • 1978-1989 Associate Professor of Medicine
  • 1990-1991 Associate Professor at the Faculty of Medicine COCHIN PORT ROYAL. University of Paris V (France). René Descartes.
  • 1991- Professor of Medicine (Rheumatology) at the University of Córdoba
  • 1998- Chief of Rheumatology, "Reina Sofía" Universitary Hospital
  • 1997-2010 Coordinator of the Spanish Group for the Study of Spondylitis (GRESSER)
  • 2005- Academic Director of the Master University ‘Research Methodology in Health Sciences’. Department of
    Medicine, University of Cordoba.
  • 2010- Co-Responsible Investigator at the IMIBIC (Instituto Maimónides de Investigación Biomedica de Córdoba)
B. Selected peer-reviewed publications (in chronological order).
  1. Disease Activity As a Major Determinant of Quality of Life and Physical Function in Patients With Early Axial Spondyloarthritis. Fernández-Carballido C, Navarro-Compán V, Castillo-Gallego C, Castro-Villegas MC, Collantes-Estévez E, de Miguel E; Esperanza Study Group. Arthritis Care Res (Hoboken). 2017 Jan;69(1):150-155.
  2. Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation. Ruiz-Limón P, Ortega R, Arias de la Rosa I, Abalos-Aguilera MD, Perez-Sanchez C, Jimenez-Gomez Y, Peralbo-Santaella E, Font P, Ruiz-Vilches D, Ferrin G, Collantes-Estevez E, Escudero-Contreras A, López-Pedrera C, Barbarroja N. Transl Res. 2016 Dec 9. pii: S1931-5244(16)30423-6.
  3. 'Atherothrombosis-associated microRNAs in Antiphospholipid syndrome and Systemic Lupus Erythematosus patients'. Pérez-Sánchez C, Aguirre MA, Ruiz-Limón P, Barbarroja N, Jiménez-Gómez Y, de la Rosa IA, Rodriguez-Ariza A, Collantes-Estévez E, Segui P, Velasco F, Cuadrado MJ, Teruel R, González-Conejero R, Martínez C, López-Pedrera Ch. Sci Rep. 2016 Aug 9;6:31375.
  4. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Moltó A, Etcheto A, van der Heijde D, Landewé R, van den Bosch F, Bautista Molano W, Burgos-Vargas R, cheung PP, Collantes-Estevez E, Deodhar A, El-Zorkany B, Erdes S, Gu J, Hajjaj-Hassouni N, Kiltz U, Kim TH, Kishimoto M, Luo SF, Machado PM, Maksymowych WP, Maldonado-Cocco J, Marzo-Ortega H, Montecucco CM, Ozgocmen S, van Gaalen F, Dougados M. Ann Rheum Dis 2015 doi: 10.1136/annrheumdis-2015-208174. [Epub ahead of print]. IF: 10.337 Q1/D1.
  5. Anticyclic citrullinated protein antibodies are implicated in the development of cardiovascular disease in rheumatoid arthritis. Barbarroja N, Perez-Sanchez C, Ruiz-Limon P, Castro-Villegas C, Aguirre MA, Carretero R, Segui P, Jimenez-Gomez Y, Sanna M, Rodriguez-Ariza A, Collantes-Estevez E, Escudero A, López-Pedrera C. Arterioscler Thromb Vasc Biol 2014;34(12):2706-16. IF: 6.008 Q1/D1
  6. Genetic variants within immune-modulating genes influence the risk of developing rheumatoid arthritis and anti-TNF drug response: a two-stage case-control study. Canet LM, Cáliz R, Lupiañez CB, Canhao H, Martinez M, Escudero A, Filipescu I, Segura-Catena J, Soto-Pino MJ, Ferrer MA, García A, Romani L, Perez-Pampin E, González-Utrilla A, Lopez-Nevot MA, Collantes E, Fonseca JE, Sainz J. Pharmacogenetic Genomics. 2015;25(9):432-43. IF: 3.481. Q1.
  7. Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs: a multicenter study. Canet LM, Filipescu I, Caliz R, Lupiañez CB, Canhao H, Escudero A, Segura-Catena J, Soto-Pino MJ, Ferrer MA, García A, Romani L, Perez-Pampin E, Gonzalez-Utrilla A, Lopez-Nevot MA, Collantes E, Fonseca JE, Sainz J. Pharmacogenet Genomics 2015;25(7):323-33. . IF: 3.481. Q1.
  8. Is spinal mobility in patients with spondylitis is determined by age, structural damage, and inflammation?. Calvo-Gutierrez J, Garrido-Castro JL, Gil-Cabezas J, Gonzalez-Navas C, Font Ugalde P, Carmona L, Collantes-Estevez E. Arthritis Care Res (Hoboken). 2015;67(1):74-9. IF: 4.713 Q1
  9. Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effets of in vivo statin treatment. Ruiz-Limon P, Barbarroja M, Pérez-Sanchez C, Aguirre MA, Bertolaccini ML, Khamashta MA, Rodriguez-Ariza A, Almaden Y, Segui P, Khraiwesh H, Gonzalez-Reyes JA, Villalba JM, Collantes-Estevez E, Cuadrado MJ, Lopez-Pedrera C. Ann Rheum Dis 2015;74(7):1450-8. IF: 10.337 Q1/D1.
  10. Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus. Perez-Sanchez C, Barbarroja N, Messineo S, Ruiz-Limon P, Rodriguez-Ariza A, Jimenez-Gomez Y, Khamashta MA, Collantes-Estevez E, Cuadrado MJ, Aguirre MA, Lopez-Pedrera C. Ann Rheumatol Dis 2015;74(7):1441-9. IF: 10.337 Q1/D1.
  11. Performance of the assessment of Spondyloarthritis international Society criteria for the classification of spondyloarthritis in early spondyloarthritis clinics participating in the ESPERANZA programme. Tomero E, Mulero J, de Miguel E, Fernandez-Espartero C, Gobbo M, Descalzo MA, Collantes-Estévez E, Zarco P, Muñoz- Fernandez S, Carmona L; ESPERANZA study group. Rheumatology 2014 53:353-60. IF: 4.212 Q1
  12. GENDER-ASSOCIATED DIFFERENCES OF DECTIN-2, DC-SIGN and MCP-1 POLYMORPHISM IN THE SUCESPTIBILITY TO RHEUMATOID ARTHRITIS. Juan Sains, Luz Canet, Carmen Belén Lupiañez, Alrjandro Escudero, Ileana Filipescu, Juan Segura-Catena, maria José Soto-Pino, Manuela Expósito Ruiz, Miguel Angel Ferrer, Antonio García, Lourdes Romaní, Alfonso González-Utrilla, Teresa Vallejo, Kari Hemminki, Asrta Forsti, Eduardo Collantes, Rafel Caliz. PLoS One. 2013 Aug 30;8(8):e72732. doi: 10.1371/journal.pone.0072732. FI 3.730; Q1
  13. VALIDITY OF ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE (ASDAS)IN PATIENTS IN PATIENTS WITH EARLY SPONDYLOARTHRITIS FROM THE ESPERANZA PROGRAM. MC. Fernandez-Espartero, E. De Miguel, E. Loza, E. Tomero, M. Gobbo, MA. Descalzo, E. Collantes-Estevez, J. Mulero, S. Munoz-Fernandez, P. Zarco, L. Carmona and ESPERANZA Study Group. Ann Rheum Dis 2014 Jul;73 (7):1350-5. F I: 9.111 Q1/D1
  14. TREATING SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS, TO TARGET: RECOMMENDATIONS OF AN INTERNATIONAL TASK FORCE. Josef S. Smolen, Jürgen Braun, Maxime Dougados, Paul Emery, Oliver FitzGerald, Philip Helliwell, Arthur Kavanaugh, Tore Kvien, Robert Landewé, Thomas Luger, Philip Mease, Ignazio Olivieri, John Reveille, Christopher Ritchlin, Martin Rudwaleit, Monika Schoels, Joachim Sieper, Martinus de Wit, Xenofon Baraliakos, Neil Betteridge, Ruben Burgos-Vargas, Eduardo Collantes-Estevez, Atul Deodhar, Dirk Elewaut, Laure Gossec, Merryn Jongkees, Mara Maccarone, Kurt Redlich, Filip van den Bosch, James Cheng-Chung Wei, Kevin Winthrop, Désirée van der Heijde. Ann Rheum Dis 2014 Jan 73(1):6-16. F I: 9.111 Q1/D1
  15. HIP DISEASE IN ANKYLOSING SPONDYLITIS. Vander Cruyssen B, Vastesaeger N, Collantes-Estévez E.Curr Opin Rheumatol. 2013; 25(4):445-454. FI:5.191 Q1
  16. BOTH CLINICAL FACTORS AND GENETIC POLYMORPHISMS INFLUENCE ON DEVELOPMENT OF SEVERE FUNCTIONAL STATUS IN ANKYLOSING SPONDYLITIS.DATA FROM REGISPONSER. Ruxandra Schiotis, MD; Nerea Bartolomé; Alejandra Sánchez; Magdalena Szczypiorska; Jesús Sanz; Eduardo Cuende; Eduardo Collantes Estevez; Antonio Martínez; Diego Tejedor; Marta Artieda; Anca Buzoianu; Juan Mulero. PLoS ONE 7(9): e43428. doi 10.1371/journal pone.0043428. FI 3.730; Q1
  17. MITOCHONDRIAL DYSFUNCTION IN ANTIPHOSPHOLIPIDID SYNDROME: IMPLICATIONS IN THE PATHOGENESIS OF THE DISEASE AND DEFECTS OF COENZYME Q10 TREATMENT. Carlos Perez- Sanchez, Patricia Ruiz-Limon, Ma Angeles Aguirre, Maria Laura Bertolaccini, Munther A. Khamashta, Antonio Rodriguez-Ariza, Pedro Segui, Eduardo Collantes-Estevez, Nuria Barbarroja, Husam Khraiwesh, Jose Antonio Gonzalez-Reyes, Jose Manuel Villalba, Francisco Velasco, Ma Jose Cuadrado, Chary Lopez-Pedrera. Blood. 2012; 119(24):5859-5870. FI 9.060; D1/Q1
  18. A HIGH DENSITY SNP GENOTYPING APPROACH WITHIN 19Q13 CHROMOSOMIC REGION IDENTIFIES AN ASSOCIATION OF A CNOT3 POLYMORPHISM WITH ANKYLOSING SPONDYLITIS. Roberto Díaz-Peña, Ana M. Aransay, Beatriz Suárez-Álvarez, Jacome Bruges-Armas, Naiara Rodríguez-Ezpeleta, María Regueiro, Fernando M. Pimentel-Santos, Juan Mulero, Alejandra Sánchez, Eduardo Collantes, Rubén Queiro, Javier Ballina, Helena Alves, Carlos López-Larrea. Ann Rheum Dis 2012; 71: 714-717. F I: 9.111 Q1/D1
  19. A 40 MONTH MULTICENTRE, RANDOMIZED PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND CARRY OVER EFFECT OF REPEATED INTRA-ARTICULAR INJECTIONS OF HYALURONIC ACID IN KNEE OSTEOARTHRITIS: THE AMELIA PROJECT. Federico Navarro-Sarabia, Pilar Coronel, Eduardo Collantes, Francisco J Navarro, Arturo Rodriguez de la Serna, Antonio Naranjo, Mercedes Gimeno and Gabriel Herrero-Beaumont. Ann Rheum Dis. 2011; 69:1097-102. F I: 9.111 Q1/D1
  20. ERAP 1 POLYMORPHISMS AND HAPLOTYPES ARE ASSOCIATED WITH ANKYLOSING SPONDYLITIS SPONDYLITIS SUSCEPTIBILITY AND FUNCTIONAL SEVERITY IN A SPANISH POPULATION. Magdalena Szczypiorska, Alejandra Sánchez, Nerea Bartolomé, David Arteta, Jesús Sanz, Elia Brito, Pilar Fernández, Eduardo Collantes, Antonio Martínez, Diego Tejedor, Marta Artieda, Juan Mulero. Rheumatology (Oxford). 2011 Nov; 50 (11):1969-75. Epub 2011 Aug 24. FI: 4.212 Q1
  21. HIGH-DOSE ETANERCEPT IN ANKYLOSING SPONDYLITIS: RESULTS OF A 12-WEEK RAMDOMIZED, DOUBLE BLIND, CONTROLLED, MULTICENTER STUDY (LOADET STUDY). Navarro Saravia F,, Fernandez- Sueiro JL, Torre-Alonso JC, Queiro R, González C, Gratacós J, Loza E, Linares l, Zarco P, Juanola X, Román Ivorra J, Martín Mola E, Sanmatí R, Mulero J, Diaz G, Armendariz Y, Collantes E. Rheumatology (Oxford). 2011 50:1828-37Jun 23. FI: 4.212 Q1
  22. FINE MAPPING OF MAJOR HISTOCOMPATIBILITY COMPLEX IN ANKYLOSING SPONDYLITIS: ASSOCIATION OF HLA- DPA1 AND HLA DPB1 REGION. Roberto Díaz-Peña, Ana M Aransay, Jacome Bruges-Armas, Antonio López-Vazquez, Naiara Rodríguez-Ezpeleta, Inaki Mandibil, Alejandra Sanchez, Juan Carlos Torre-Alonso, Bruno F. Bettencourt, Juan Mulero, Eduardo Collantes, Carlos Lopez Larrea. Arthritis and Rheumatism 63:3305–3312 2011. F I: 7.477 Q1 D1
  23. 2010 UPDATE OF THE ASAS/EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF ANKYLOSING SPONDYLITIS. J Braun, R van den Berg, X Baraliakos, H Boehm, R Burgos-Vargas, E Collantes-Estevez, et al., Ann Rheum Dis 2011;70 896-904 F I: 9.111 Q1/D1
  24. PREDICTING THE OUTCOME OF ANKYLOSING SPONDYLITIS THERAPY. N. Vastesaeger, D. van der Heijde, R. D. Inman, Y. Wang, A. Deodhar, B. Hsu, M. Rahman B. Dijkmans, P. Geusens, B. Vander Cruyssen, E. Collantes, J. Sieper, J. Braun. Ann Rheum Dis 2011; 70: 973-981 F I: 9.111 Q1/D1
  25. A MODEL FOR THE DEVELOPMENT AND IMPLEMENTATION OF A NATIONAL PLAN FOR THE OPTIMAL MANAGEMENT OF EARLY SPONDYLOARTHRITIS: THE ESPERANZA PROGRAM. Santiago Muñoz-Fernández, Loreto Carmona, Eduardo Collantes, Juan Mulero, M. Jesús García-Yébenes, Eugenio de Miguel, Raquel Almodovar, Cristina Fernández-Carballido, José Francisco García Llorente, Milena Gobbo, for the Esperanza Group. Ann Rheum Dis. 2011;70 827-830 F I: 9.111 Q1/D1
  26. GLOBAL EFFECTS OF FLUVASTATIN ON THE PROTHROMBOTIC STATUS OF PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME. Chary López-Pedrera, Patricia Ruiz-Limón, Maria Ángeles Aguirre, Nuria Barbarroja, Carlos Pérez-Sánchez, Paula Buendía, Ines-Carmen Rodriguez-Gacía, Antonio Rodriguez-Ariza, Eduardo Collantes-Estevez, Francisco Velasco, Munther Khasmahta, Maria José Cuadrado. Ann Rheum Dis. 2011; 70(4): p. 675-682. F I: 9.111 Q1/D1
  27. USEFULNESS OF A CENTRALIZED SYSTEM OF DATA COLLECTION FOR THE DEVELOPMENT OF AN INTERNATIONAL MULTICENTER REGISTRY OF SPONDYLOARTHRITIS. Ruxandra Schiottis, P. Font, A. Escudero, P. Zarco, R. Almodovar, J. Gratacós, J. Mulero, X. Juanola, C. Montilla, E. Moreno, R. Ariza Ariza, E. Collantes-Estevez on behalf REGISPOSER working group*. Rheumatology (Oxford). 2011. 50(1):132-6.FI: 4.212 Q1
  28. “ASSOCIATION OF KIR3DS1*013 AND KIR3DL1*004 ALLELES WITH SUSCEPTIBILITY TO ANKYLOSING SPONDYLITIS.” Roberto Díaz-Peña, Jose Ramón Vidal-Castiñeira, Rebeca Alonso-Arias, Jose Luis Vicario, Rafael Solana, Eduardo Collantes, Antonio López-Vázquez Jesús Martínez-Borra, Carlos López-Larrea. Arthritis Rheumatism 62:1000–1006. 2010. F I: 7.477 Q1/ D1
  29. Differential expression of protease-activated receptors (PARs) in monocytes from patients with primary antiphospholipid syndrome. Chary López-Pedrera, Maria Ángeles Aguirre, Paula Buendía, Nuria Barbarroja, Patricia Ruiz-Limón, Eduardo Collantes-Estevez, Francisco Velasco, Munther Khasmahta, Maria José Cuadrado. Arthritis Rheumatism March 2010; 62 (3); 869-877 F I: 7.477 Q1/ D1
  30. Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery Bert Vander Cruyssens, Elisa Muñoz-Gomariz, Pilar Font, Juan Mulero, Kurt de Vlan, Annelies Boonen, Janitzia Vazquez-Mellado Cervantes, Diana Flores, Nathan Vastesaeger and Eduardo Collantes. Rheumatology (Oxford) 2010 Jan; 49(1):73-81. FI: 4.212 Q1
  31. The Development of Assessment of Spondyloarthritis International Society (ASAS) Clasification Criteria for Axial Spondyloarthritis (Part II): Validation and Final Selection. M Rudwaleitt, R Landewé, D van der Heijden, J Listing, N Akkoc, J Brandt, J Braun, CT Chou, E Collantes-Estévez, J Davis, B Djikmans, M Dougados, P Emery, Bruisma, R Inman, MA Khan, M Leirisalo-Repo, J van der Linden, WP Maksymowiych, H Mielants, K de Vlan, J Siepper. Ann Rheum Dis 2009 Jun;68(6):777-83. F I:9.111 Q1/D1
  32. The Development of Assessment of Spondyloarthritis International Society (ASAS) Clasification Criteria for Axial Spondyloarthritis (Part I): Clsification of paper patients by expert opinion including uncertainty appraisal. M Rudwaleitt, R Landewé, D van der Heijden, J Brandt, J Braun, R Burgos Vargas, E Collantes-Estévez, J Davis, B Djikmans, M Dougados, P Emery, Bruisma, R Inman, MA Khan, M Leirisalo-Repo, J van der Linden, WP Maksymowiych, H Mielants, K de Vlan, J Siepper. Ann Rheum Dis 2009 Jun;68(6):770-6. F I: 9.111 Q1/D1
  33. New criteria for inflammatory back pain in patients with chronic back pain – a real patient exercise of the Assessment in SpondyloArthritis international Society (ASAS). Joachim Sieper, Désirée van der Heijde, Robert BM Landewé, Jan Brandt, Ruben Burgos-Vargas, Eduardo Collantes Estévez, Ben AC Dijkmans, Maxime Dougados, Muhammad Asim Khan, Marjatta Leirisalo-Repo, Sjef van der Linden, Walter P Maksymowych, Herman Mielants, Ignazio Olivieri, and Martin Rudwaleit. Ann Rheum Dis. 2009 Jun;68(6):784-8. F I: 9.111 Q1/D1
  34. Infliximab reduces myeloperoxidase concentration in chronic inflammatory joint diseases. Montserrat Feijóo, Isaac Túnez, Inmaculada Tasset, Pedro Montilla, Verónica Pérez-Guijo, Elisa Muñoz-Gomariz, Adela Ruiz, Ruxandra Schiotis and Eduardo Collantes. Pharmacology 2009; 83 (4): 211-6. Epub 2009 Feb 7. F I: 1.603
  35. First Signs and Symptoms of Spondyloarthritis. Data From an Inception Cohort with a disease course of two years or less (REGISPONSER- Early). M. Rojas-Vargas, E. Muñoz-Gomariz, A. Escudero, P. Font, P. Zarco, R. Almodovar, J. Gratacós,J. Mulero, X. Juanola, C. Montilla, E. Moreno, E. Collantes on behalf REGISPOSER working group*. Rheumatology (Oxford) 2009; 48 (4): 404-409. FI: 4.212 Q1
  36. Adalimumab effectively reduces the signs and symptons of active ankylosing spondylitis in patients with total spinal ankylosis. D van der Heijden, Aileen Pangan, Michael H Schiff, Jürgen Braun, Michael Borofky, Juan Torre, Jonh C Davis, Robert L Wong, Harmurt Kupper and Eduardo Collantes. Ann Rheum Dis 2008;67;1218-1221. F I: 9.111 Q1/D1
C. Research Support.

Ongoing Research Support

  • PRECISESADS (# 115565) 02/01/2014-01/31/2019
    Innovative Medicines Iniciative (IMI). European Union
    Molecular reclassification to find clinically useful biomarkers for systemic autoimmune diseases.
    Head researcher: Marta Alarcón.
    Role: Key investigator
  • CTS-7940 04/15/2012-04/14/2016
    Consejería de Innovación, Ciencia y Empresa, Junta de Andalucia. Incentivos a Proyectos de Excelencia.
    Cellular and molecular mechanisms of athero-thrombosis in systemic autoimmune diseases: epigenetic study and análisis of the effects of new therapeutic modalities’
    Role: Key Investigator

Recent Completed Research Support

  • PI-0314-2012 01/01/2013-12/31/2015
    Consejeria de Salud. Secretaria General de Calidad y Modernización
    Study of new molecular targets involved in inflammation and fibrous tissue apposition and bone in ankylosing spondylitis. Therapeutic alternatives.
    Role: Key Investigador
  • PI-0049-2011 17/05/2012-17/05/2015
    Fundación Publica andaluza Progreso y Salud
    Biomechanical analysis of movement and balance for assessment of the effectiveness of intra-articular therapies in patients with knee osteoarthritis.
    Role: Associated investigator
  • PI10/01524 01/01/2011-12/31/2013
    Fondo de Investigación Sanitaria (FIS), Health Ministry of Spain.
    Monitoring of therapeutic response with a new metrological index in ankylosing spondilitis patients.
    Role: Principal Investigator
  • P08-CVI-04234 01/01/2009-12/31/2013
    Consejeria de Innovacion, Ciencia y Exmpresa, Junta de Andalucia. Incentivos a Proyectos de Excelencia
    “Study of the cellular and molecular mechanisms involved in the response of APS and SLE patients to the treatment with Fluvastatin and new antioxidant drugs. Genomic and proteomic approaches”.
    Role: Associated investigator
  • PI-2010-0243 01/01/2010-12/31/2012
    Consejeria de Salud. Secretaria General de Calidad y Modernización
    Using a motion analysis system for the assessment of the effectiveness of biological therapies in patients with ankylosing spondylitis.
    Role Principal Investigator
  • PI08/90319 01/01/2009-12/31/2011
    Fondo de Investigación Sanitaria (FIS), Health Ministry of Spain.
    Validation of a three-dimensional motion capture video based assessment of mobility in patients with ankylosing spondylitis.
    Role Principal Investigator